Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Rating of “Hold” by Brokerages

Rapt Therapeutics (NASDAQ:RAPT) has earned an average rating of “Hold” from the thirteen research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $48.4444.

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Rapt Therapeutics to a “hold” rating in a report on Saturday, March 7th. TD Cowen lowered shares of Rapt Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Lifesci Capital cut shares of Rapt Therapeutics from an “outperform” rating to a “hold” rating in a research report on Tuesday, January 20th. Guggenheim downgraded shares of Rapt Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Finally, HC Wainwright lowered shares of Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price objective on the stock. in a report on Tuesday, January 20th.

Institutional Trading of Rapt Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in RAPT. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Rapt Therapeutics in the 4th quarter valued at $46,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Rapt Therapeutics during the fourth quarter worth $153,000. Bank of Nova Scotia bought a new stake in Rapt Therapeutics in the fourth quarter valued at about $227,000. Voloridge Investment Management LLC bought a new stake in Rapt Therapeutics in the fourth quarter valued at about $233,000. Finally, Virtus Investment Advisers LLC acquired a new position in Rapt Therapeutics in the fourth quarter valued at about $245,000. Institutional investors own 99.09% of the company’s stock.

Rapt Therapeutics Stock Performance

NASDAQ:RAPT opened at $58.02 on Monday. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -5.25 and a beta of 0.49. The stock’s fifty day moving average price is $57.41 and its two-hundred day moving average price is $39.54. Rapt Therapeutics has a 52-week low of $5.67 and a 52-week high of $58.02.

About Rapt Therapeutics

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.